Amgen Beats Decade-Old Investor Suit Over Off-Label Scheme

Law360, Los Angeles (January 10, 2017, 10:25 PM EST) -- A California judge Tuesday dismissed a decade-old action claiming Amgen Inc.’s board caused more than $1 billion in damages by overseeing an off-label drug marketing scheme, saying the shareholder failed to make a demand on the officials to instigate litigation before filing her suit.

Shareholder Judy Durgin’s suit, brought in May 2007, relates to allegedly misleading statements the pharmaceutical giant made about off-label uses for two of its drugs, Aranesp and Epogen. In 2012, the company pled guilty in federal court to misbranding Aranesp and agreed...
To view the full article, register now.




Case Information

Case Title

Judy Durgin v. Kevin W Sharer et al

Case Number



California Central

Nature of Suit

Stockholders Suits


Philip S. Gutierrez

Date Filed

May 7, 2007

Law Firms


Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.